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Background
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3 ITD) mutation is related to 
poor prognosis in normal-karyotype acute myeloid leukemia (AML). However, the prog-
nostic significance of the mutation at relapse has not been adequately investigated. We 
investigated the prognostic significance of the FLT3 ITD mutation at relapse in normal-kar-
yotype AML patients. 
Methods
We analyzed 69 normal-karyotype AML patients, in whom paired bone marrow samples 
taken at initial diagnosis and subsequent relapse were analyzed for the FLT3 ITD mutation 
at the Asan Medical Center between 1995 and 2009. 
Results
Forty patients showed a persistent wild-type genotype, 11 showed the FLT3 ITD mutation 
at diagnosis and relapse, and 9 lost and another 9 acquired the mutation at relapse. The 
mutation status at relapse affected the overall survival (OS), with the mutation group 
showing shorter OS and survival after relapse than the wild-type group did (P＜0.001 
and P＜0.001, respectively), despite having received more frequent stem cell trans-
plantation after relapse than the wild-type group did. However, no difference was detected 
in the OS and survival after relapse with regard to the mutation status at diagnosis. 
Conclusion
The patients with FLT3 ITD mutation at relapse showed poorer prognoses than those with-
out the mutation. However, mutation status at diagnosis did not affect the outcome. These 
results suggest that, in normal-karyotype AML patients with relapse, the prognostic sig-
nificance of FLT3 ITD mutation at relapse is greater than that of the mutation status at 
diagnosis.
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INTRODUCTION
The Fms-like tyrosine kinase 3 (FLT3) gene encodes a 
class III receptor tyrosine kinase that plays important roles 
in cellular proliferation and differentiation [1-8]. To date, 
2 types of FLT3 mutations have been found to induce auto-
phosphorylation through ligand-independent FLT3 dimeri-
zation, leading to uncontrolled hematologic progenitor cell 
proliferation and malignancy. One such mutation is an in-
ternal tandem duplication (ITD) of the region between exon 
14 and 15 encoding the juxtamembrane domain; the other, 
in exon 20, is a point mutation in aspartic acid residue 835 
(D835) within the activation loop of the second tyrosine 
kinase domain [9, 10]. The FLT3 ITD mutation is found 
in approximately 30% of newly diagnosed acute myeloid 
leukemia (AML) patients, and an association of the mutation 
with poor prognostic indicators, such as leukocytosis, higher 
marrow blast counts, shorter overall survival (OS) and 
event-free survival (EFS), and higher relapse rates, has been 
firmly established in those with newly diagnosed AML, espe-
cially in the intermediate cytogenetic risk group [11-16]. Korean J Hematol 2011;46:88-95.
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The FLT3 D835 mutation occurs less frequently than the 
FLT3 ITD mutation does, and the prognostic significance 
of this mutation in newly diagnosed AML patients is less 
clear, with previous studies reporting conflicting outcomes 
[17-19]. In addition to the FLT3 ITD mutation, mutations 
in the nucleophosmin1 (NPM1) gene are the most frequent 
genetic alterations, being found in approximately 50% of 
patients with normal-karyotype AML, and known to be asso-
ciated with better response to induction therapy and a more 
favorable outcome in the absence of FLT3 ITD mutations 
[20]. 
Thus far, the prognostic impact of the FLT3 ITD mutation 
at relapse has not been adequately evaluated in patients 
with normal-karyotype AML. Therefore, we analyzed FLT3 
ITD mutation status at diagnosis and relapse in patients with 
normal-karyotype AML relapse, and investigated the prog-
nostic significance of FLT3 ITD mutation at relapse.
 MATERIALS AND METHODS
1. Selection of patients and assessment of clinical variables 
Paired bone marrow samples collected at diagnosis and 
relapse from 69 patients newly diagnosed with normal-kar-
yotype AML between 1995 and 2009 at Asan Medical Center 
were analyzed for FLT3 ITD mutation status. Data for clinical 
variables, including CBC, blast counts in peripheral blood 
(PB) and bone marrow (BM), karyotype at initial diagnosis 
and relapse, and implementation of stem cell transplantation 
(SCT) were obtained from all patients. The dates of initial 
diagnosis, first complete remission (CR), first relapse, SCT 
performance, and death were established by performing a 
retrospective review of the patients’ medical records. CR 
was defined as the presence of less than 5% blasts with 
more than 20% cellularity in a standardized BM aspirate 
after the first or second course of induction chemotherapy. 
Relapse was defined as more than 5% leukemic blasts in 
BM aspirates in patients who had previously achieved CR 
state. OS was defined as the time from diagnosis to death 
or last follow-up, and survival after relapse was defined as 
the time from first relapse to death or last follow-up. 
2. Cytogenetic analysis
Cytogenetic analyses were performed on at least 20 meta-
phases using paired diagnosis and relapse BM samples. 
According to the classification system proposed by the US 
Southwest Oncology Group (SWOG), cytogenetic abnormal-
ities at relapse were grouped into 4 categories [21]: (1) good- 
prognosis: inv(16)/t(16;16)/del(16q) or t(8;21) lacking del(9q) 
and complex karyotypes; (2) intermediate-prognosis: normal 
karyotype, +8, +6, Y, and del(12p); (3) poor-prognosis: 5/del 
(5q), 7/del(7q), abn(3q), t(6;9) and complex karyotypes; (4) 
unknown-prognosis: all the other above-mentioned abnor-
malities.
3. Patient treatment 
All patients received standard induction chemotherapy 
with cytarabine and daunorubicin. This regimen included 
continuous intravenous infusion of 200 mg/m
2/day (100 mg/ 
m
2/day for patients aged ＞60 years) of cytarabine on days 
1-7 and 45 mg/m
2/day of daunorubicin on days 1-3. Patients 
who failed to achieve CR, but attained partial remission 
(PR) received a second identical cycle of induction chemo-
therapy. At relapse, the patients received the same regimen 
of induction chemotherapy used following the initial 
diagnosis. Depending on patient age and availability of a 
suitable donor, the patients received autologous or allogeneic 
SCT on the first CR status or later. Patients with FLT3 ITD 
mutation at initial diagnosis were preferentially invited to 
receive autologous or allogeneic SCT at the first CR status. 
However, there was no difference in the induction chemo-
therapy regimen according to FLT3 ITD mutation status 
at initial diagnosis or relapse.
4. Detection of FLT3 ITD and NPM1 mutations 
FLT3 ITD and NPM1  mutations were identified using 
PCR-capillary electrophoresis methods. Genomic DNA was 
extracted from BM mononuclear cells using the Qiagen DNA 
purification kit (Qiagen, Hilden, Germany) and stored at 
-20
oC. Primer sets were designed to detect the FLT3 ITD 
and  NPM1  4 base pair insertion mutations. Additionally, 
a specific set of HBG primers was used to ascertain DNA 
integrity and validate the precision of PCR amplification. 
The sequences of the primers specific to FLT3, NPM1, and 
HBG were as follows. FLT3 primers: forward, 5'-FAM-AGCA 
ATT TAG GTA TGA AAG CCA GCTA-3'; reverse, 5'-CTT 
TCA GCA TTT TGA CGG CAA CC-3'. NPM1 primers: for-
ward, 5'-GTT TCT TTT TTT TTT TTT CCA GGC TAT TCA 
AG-3', reverse, 5'-HEX-CAC GGT AGG GAA AGT TCT 
CAC TCT GC-3'. HBG primers: forward, 5'-HEX-CCA GAA 
GAG CCA AGG ACA GGT ACG-3', reverse, 5'-AGA TCC 
CCA AAG GAC TCA AAG AAC C-3'. The 20 μL multiplex 
PCR reaction solution consisted of 200 ng of genomic DNA, 
20 pmol of each primer, 25 mmol/L MgCl2, 2.5 mmol/L 
dNTP, 2 μL of 10× PCR buffer, 0.2 μL of Qiagen HotTaq 
DNA polymerase and water. The PCR conditions were as 
follows: the mixture was heated to 95
oC for 15 min for 
initial denaturation, and then 35 cycles of 95
oC for 20 sec, 
60
oC for 40 sec, and 72
oC for 40 sec were performed, followed 
by a final extension phase of 72
oC for 30 min. The PCR 
products were then diluted 1:30 and analyzed by capillary 
electrophoresis using ABI 310 genetic analyzer (Applied 
Biosystems Inc., Foster city, CA, USA) and GeneScan Analysis 
software (version 1.2, Applied Biosystems Inc., Foster City, 
CA, USA). The data is represented as a ratio of mutant 
cells:wild-type cells. The lowest detection limit of this proto-
col was 5%, which had been determined by previous serial 
dilution experiments [22]. For the specimens, in which NPM1 
mutation was detected, additional direct sequencing was per-
formed to confirm the mutation subtype. 
5. Analysis of clinical variables related to FLT3 ITD paired mu-
tation status at diagnosis and relapse
An analysis of clinical variables related to FLT3 ITD muta-Korean J Hematol 2011;46:88-95.
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tion status at diagnosis and relapse was performed. Results 
were grouped into 4 categories: (1) persistent wild type: 
NN (negative at diagnosis and relapse); (2) acquired mutation: 
NP (negative at diagnosis and positive at relapse); (3) loss 
of mutation: PN (positive at diagnosis and negative at relapse); 
and (4) persistent mutation: PP (positive at diagnosis and 
relapse). The clinical variables described above were com-
pared individually between NN and PN, NN and NP, NN 
and PP, and PN and PP groups. Two additional comparisons 
were made: between patients positive for FLT3 ITD mutation 
at relapse (NP+PP) and those negative for FLT3 ITD mutation 
at relapse (NN+PN), and between patients positive for FLT3 
ITD mutation at diagnosis (PN+PP) and those negative for 
FLT3 ITD mutation at diagnosis (NN+NP). Additionally, we 
compared the prognosis in patients without FLT3 ITD muta-
tion stratifying according to NPM1 mutation status at diag-
nosis or relapse to identify the prognostic impact of NPM1 
mutations. We also compared the prognosis of patients on 
the basis of FLT3 ITD mutant:wild-type ratio in patients 
with the mutation at diagnosis or relapse in order to evaluate 
the effect of the amount of mutation on the prognosis.
6. Multivariate analysis of OS and survival after relapse with 
respect to variables, including FLT3 ITD mutation status at 
diagnosis and relapse
Multivariate analysis of OS and survival after relapse with 
respect to FLT3 ITD mutation status at diagnosis and relapse 
was performed. For the analysis at diagnosis, WBC counts 
and blast percentage in PB and BM, which were found to 
be significantly different among FLT3 ITD mutation groups 
in univariate analysis, were used to adjust the relevant out-
comes. For the analysis at relapse, duration of CR and SCT 
performance rates after relapse, which showed significant 
differences among FLT3 ITD mutation groups in univariate 
analysis, were used to adjust the dependent measures.
7. Statistical analysis
Pearson’s chi-squared or Fisher’s exact tests (for small 
numbers) were used to compare categorical variables. Mann- 
Whitney U test was used to compare continuous variables. 
Estimations of OS and survival after relapse were performed 
using Kaplan-Meier methods and compared using log-rank 
test. Multivariate analyses of OS and survival after relapse 
were performed using Cox’s proportional hazards model. 
For all analyses, tests were two-tailed, and P-values≤0.05 
were considered statistically significant. All calculations were 
performed using SPSS 13.0.1 for Windows (SPSS Inc, 
Chicago, IL, USA).
RESULTS
1. Overall patient characteristics 
All patients achieved first CR after a median interval of 
32.0 days and relapsed within a median of 7.6 months from 
the first CR. A second CR was achieved in 26 patients (37.7%), 
of whom 8 (30.8%) relapsed again after the second round 
of induction chemotherapy. Fifty-five patients (79.7%) died 
after relapse with a median interval of 3.8 months. The 
FLT3 ITD mutation was detected in 20 patients (29.0%) 
at diagnosis and relapse, with median mutant:wild-type ratio 
as 0.3 (range, 0.05-4.36) and 0.3 (range, 0.05-9.94) at diagnosis 
and relapse, respectively. The NPM1 mutation was detected 
in 19 (27.5%) and 13 (18.8%) patients at diagnosis and relapse, 
with median mutant:wild-type ratio as 0.55 (range, 0.16-0.86) 
and 0.55 (range, 0.07-0.75) at diagnosis and relapse, respec-
tively. Among the 19 patients who showed NPM1 mutation 
at diagnosis, 16 (84.2%) had NPM1 type-A mutation. Among 
the 13 patients who showed NPM1 mutation at relapse, 
10 (76.9%) had NPM1 type-A mutation. The remaining 3 
patients had NPM1 type-D mutation at diagnosis and relapse. 
Cases showing a change of NPM1 mutation type from diag-
nosis to relapse were not found. 
2. Comparison of clinical variables and prognosis between 
patients with different paired FLT3 ITD mutation status 
Tables 1 and 2 show comparisons of the clinical variables 
and prognosis between patients with different FLT3 ITD 
mutation status at diagnosis and relapse. SCT performance 
rates at the first CR ranged from 25.0% to 44.4%, which 
is variable but this variation was not driven by FLT3 ITD 
mutation status at diagnosis and relapse. However, SCT per-
formance rates after the first relapse were significantly 
different. Patients with acquired or persistent FLT3 ITD 
mutation at relapse more frequently underwent SCT than 
those with persistent negative status did (55.6% or 63.6% 
vs. 20.0%; P=0.043, 0.009, respectively). There was no prog-
nostic impact of being in the poor cytogenetic risk group 
at relapse (OS: 20.6 vs. 22.0 months, P=0.950; duration of 
CR: 7.5 vs. 8.9 months, P=0.669; survival after relapse: 10.2 
vs. 14.3 months, P=0.214). 
The PP group showed a significantly shorter median dura-
tion of CR (6.9 months) than the NN group (10.3 months; 
P=0.045); the PP group also showed a significantly higher 
median WBC count (44.1×10
9/L vs. 8.8×10
9/L; P=0.046) than 
the NN group, but these variables did not differ between 
the PP and PN groups. The PN group showed significantly 
higher median WBC counts (66.1×10
9/L vs. 8.8×10
9/L; 
P=0.011) and blast percentages in PB (85.0% vs. 38.5%, 
P=0.006) and in BM (87.0% vs. 60.2%, P=0.001) than the 
NN group. The median OS was significantly shorter in the 
NP (9.2 months; P=0.002) and the PP (12.1 months; P=0.003) 
groups than in the NN group (19.5 months). The median 
survival after relapse was also significantly shorter in the 
NP (5.3 months; P=0.017) and the PP (4.9 months; P=0.024) 
groups than in the NN group (10.3 months). The median 
OS and survival after relapse in the PP group was significantly 
shorter than that in the PN group (45.5 months and 43.5 
months;  P=0.025 and 0.028, respectively). 
3. Comparison of clinical variables and prognosis between 
groups with different FLT3 ITD mutation status at diagnosis 
and relapse
Table 3 shows 2 additional comparisons of clinical variables Korean J Hematol 2011;46:88-95.
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Table 1. Comparison of clinical variables between patients with different paired FLT3 ITD mutation status. 
Clinical variables
Number of patients with FLT3 ITD mutation status
(% with each status)
P
NN PN NP PP NN vs. PN NN vs. NP NN vs. PP PN vs. PP
Sex (M：F) 25：15 5：44 ：5 8：3n s n s n s n s
Age, median (range) 54.0 41.0 59.0 45.0 ns ns ns ns
(6.0-79.0) (27.0-70.0) (5.0-73.0) (23.0-73.0)
FAB classification
　M0     2 (5.0) 0 0 0
　M1     11 (27.5) 5 (55.6) 2 (22.2)   2 (18.2)
　M2     15 (37.5) 3 (33.3) 5 (55.6)   3 (27.3)
　M4     3 (7.5) 0 1 (11.1)   6 (54.5)
　M5     1 (2.5) 1 (11.1) 0 0
　M6       4 (10.0) 0 0 0
　M7       4 (10.0) 0 1 (11.1) 0
Karyotype at relapse 
　Good 0 0 0 0
　Intermediate     29 (72.5) 8 (88.9)  7 (77.8)   7 (63.6)
　Poor       5 (12.5) 1 (11.1) 0 1 (9.1)
　Unknown       6 (15.0) 0 2 (22.2)   3 (27.3)
Clonal evolution
　No     27 (67.5) 8 (88.9)  7 (77.8)    7 (63.6)
　Yes     13 (32.5) 1 (11.1) 2 (22.2)   4 (36.4)
SCT in 1
st CR status
　No     30 (75.0) 5 (55.6) 6 (66.7)   7 (63.6) ns ns ns ns
　Yes     10 (25.0) 4 (44.4) 3 (33.3)   4 (36.4)
SCT after 1
st relapse
　No     32 (80.0) 7 (77.8) 4 (44.4)   4 (36.4)  ns 0.043 0.009 ns
　Yes   　8 (20.0) 2 (22.2) 5 (55.6)   7 (63.6)
NPM1 mutation status
　Persistent wild-type (NN)     35 (87.5) 6 (66.7) 6 (66.7)   3 (27.3)
　Lost at relapse (PN) 　2 (5.0) 2 (22.2) 0   2 (18.2)
　Persistent mutation (PP)  　3 (7.5) 1 (11.1) 3 (33.3)   6 (54.5)
Laboratory findings at diagnosis, median
　Hb (g/dL)   8.1    8.4    9.0    9.3  ns ns ns ns
　WBC (×10
9/L)   8.8  66.1  39.6  44.1  0.011 ns 0.046 ns
　PLT (×10
9/L) 56.0 29.0 96.0 50.5  ns ns ns ns
　PB blasts (%) 38.5  85.0  60.0  64.0  0.006 ns ns ns
　BM blasts (%) 60.2  87.0  58.4  61.2  0.001 ns ns ns
Abbreviations: FAB, French-American-British classification; CR, complete remission; FLT3 ITD, fms-like tyrosine kinase3 internal tandem 
duplication; NN, negative at diagnosis and relapse; PN, positive at diagnosis and negative at relapse; NP, negative at diagnosis and positive at 
relapse; PP, positive at diagnosis and relapse; ns, not significant; Hb, hemoglobin; WBC, white blood cell; PLT, platelet; PB, peripheral blood;
BM, bone marrow; SCT, stem cell transplantation; NPM1, nucleophosmin. 
Table 2. Comparison of prognosis between patients with different paired FLT3 ITD mutation status. 
Prognostic variables
FLT3 ITD mutation status P
NN PN NP PP NN vs. PN NN vs. NP NN vs. PP PN vs. PP
Duration of CR, median (months) 10.3    6.6  5.4    6.9  ns ns 0.045 ns
Overall survival, median (months) 19.5 45.5 9.2 12.1 ns 0.002 0.003 0.025
Survival after relapse, median (months) 10.3 43.5 5.3   4.9 ns 0.017 0.024 0.028
Abbreviations: CR, complete remission; FLT3 ITD, fms-like tyrosine kinase3 internal tandem duplication; NN, negative at diagnosis and relapse;
PN, positive at diagnosis and negative at relapse; NP, negative at diagnosis and positive at relapse; PP, positive at diagnosis and relapse; ns, not
significant.
between groups with different FLT3 ITD mutation status 
at diagnosis and relapse. A comparison between the NN+NP 
group, which comprised patients with negative FLT3 ITD 
mutation status at diagnosis, and the PN+PP group, which 
included patients with positive FLT3 ITD mutation status 
at diagnosis, showed that the median WBC count at diagnosis 
was significantly higher in the PN+PP group (44.1×10
9/L) 
than in the NN+NP group (12.4×10
9/L; P=0.007). Moreover, Korean J Hematol 2011;46:88-95.
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Table 3. Comparison of clinical variables and prognosis between groups with different FLT3 ITD mutation status at diagnosis and relapse.
Clinical variables
FLT3 ITD status (% with each status) P
NN+NP (Negative 
at diagnosis)
PN+PP (Positive 
at diagnosis)
NN+PN (Negative 
at relapse)
NP+PP (Positive 
at relapse)
NN+NP vs.
PN+PP
NN+PN vs. 
NP+PP
Sex (M：F) 29：20 13：73 0 ：19 12：8 ns ns
Age, median (range)  56.5 41.0 53.0 55.0 ns ns
(5.0-79.0) (5.0-79.0) (6.0-79.0) (5.0-79.0)
SCT in 1
st CR status
　No 36 (73.5) 12 (66.7) 35 (71.4) 13 (65.0) ns ns
　Yes 13 (26.5)   8 (33.3) 14 (28.6)   7 (35.0)
SCT after 1
st relapse
　No 36 (73.5) 11 (55.0) 39 (79.6)   8 (33.3)  ns ＜0.001
　Yes 13 (26.5)   9 (45.0) 10 (20.4) 12 (66.7)
Laboratory findings at diagnosis, median
　Hb (g/dL)   8.3   8.6   8.1   8.9 ns ns
　WBC (×10
9/L) 12.4 44.1 17.1 39.5 0.007 ns
　PLT (×10
9/L) 58.0 41.0 51.0 69.0 ns ns
　PB blasts (%) 47.0 68.0 55.0 60.0 0.006 ns
　BM blasts (%) 61.3  87.0  64.6 64.2  0.005 ns
Duration of CR median (months)    8.6   6.9 10.0   6.8 ns    0.034
Overall survival, median (months) 17.6 13.7 23.1 12.0 ns ＜0.001
Survival after relapse, median (months)     6.9   6.4 11.8   5.5 ns ＜0.001
Abbreviations: CR, complete remission; Hb, hemoglobin; WBC, white blood cell; PLT, platelet; PB, peripheral blood; BM, bone marrow; SCT,
stem cell transplantation; FLT3 ITD, fms-like tyrosine kinase3 internal tandem duplication; NN, negative at diagnosis and relapse; PN, positive
at diagnosis and negative at relapse; NP, negative at diagnosis and positive at relapse; PP, positive at diagnosis and relapse; ns, not significant.
Fig. 1. Comparison of overall survival (A) and survival after relapse (B) between patients positive and negative for FLT3 ITD mutation at diagnosis.
the PN+PP group showed significantly higher blast percent-
age in PB (68.0% vs. 47.0%; P=0.006) and in BM (87.0% 
vs. 61.3%, P=0.005) than the NN+NP group did. However, 
there was no difference in the duration of CR, there was 
no difference in OS and survival after relapse between these 
groups (Fig. 1). Another comparison was performed between 
the NN+PN group, which included patients with negative 
FLT3 ITD mutation status at relapse, and the NP+PP group, 
which included patients with positive FLT3 ITD mutation 
status at relapse, revealed that the median duration of CR 
was significantly shorter in the NP+PP group (6.8 months) 
than in the NN+PN group (10.0 months; P=0.034). In partic-
ular, the median OS was significantly shorter in the NP+PP 
group (12.0 months) than in the NN+PN group (23.1 months; 
P＜0.001), as was survival after relapse (5.5 vs. 11.8 months; 
P＜0.001), despite the fact that SCT was performed sig-
nificantly more frequently in the NP+PP group than in the 
NN+PN group after the first relapse (66.7% vs. 20.4%; P
＜0.001) (Fig. 2). 
4. Comparison of prognosis in patients without FLT3 ITD mu-
tation stratified by NPM1 genotype status at diagnosis and 
relapse
 Patients with NPM1 mutation at diagnosis showed a trend Korean J Hematol 2011;46:88-95.
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Table 4. Multivariate analysis of OS and survival after relapse with respect to FLT3 ITD mutation status at diagnosis and relapse.
Clinical variables
Overall survival Survival after relapse
HR (95% CI) P HR (95% CI) P
FLT3 ITD mutation at relapse  2.486 (1.203-5.138) 0.014
a) 2.042 (1.062-4.045) 0.039
a)
 (compared with negative at relapse)
FLT3 ITD mutation at diagnosis  1.084 (0.528-2.144) ns
b) 1.147 (0.534-2.447) ns
b)
 (compared with negative at diagnosis)
a)P-value was adjusted for WBC count, duration of CR, blast percentage in PB and BM at diagnosis, and SCT performance rates after 1
st relapse,
b)P-value was adjusted for WBC count and blast percentage in PB and BM at diagnosis.
Abbreviations: HR, hazard ratio; FLT3 ITD, fms-like tyrosine kinase3 internal tandem duplication; ns, not significant; CI, confidence interval.
Fig. 2. Comparison of overall survival (A) and survival after relapse (B) between patients positive and negative for FLT3 ITD mutation at relapse.
towards a better outcome, such as longer OS (24.6 vs. 17.3 
months; P=0.173) and duration of CR (10.0 vs. 7.5 months; 
P=0.558) than those without NPM1 mutation at diagnosis. 
However, these differences were not statistically significant. 
Patients with NPM1 mutation at relapse also showed no 
differences in OS (15.4 vs. 23.1 months; P=0.609) and dura-
tion of CR (8.6 vs. 10.3 months; P=0.657) compared with 
those without NPM1 mutation at relapse. 
5. Comparison of prognosis in patients with FLT3 ITD muta-
tion at diagnosis or relapse according to the amount of FLT3 
ITD mutants
The high/low cut-off ratio was set at 0.66, as described 
in a previous study [23]. Six patients with a high mutant:wild 
ratio (≥0.66) at diagnosis showed trends towards shorter 
OS (9.3 vs. 22.5 months; P=0.370) and duration of CR (4.1 
vs. 6.6 months; P=0.682) than 14 patients with a low ratio 
(＜0.66) at diagnosis, suggesting possible poor prognosis, but 
the results were not statistically significant. Eight patients 
with high mutant:wild ratios (≥0.66) at relapse also showed 
similar OS (9.2 vs. 10.1 months; P=0.734) and duration of 
CR (4.1 vs. 5.4 months; P=0.701) as shown by 12 patients 
with a low ratio (＜0.66) at relapse.
6. Multivariate analysis of OS and survival after relapse re-
lated to FLT3 ITD mutation status at diagnosis and relapse 
Table 4 shows the results of multivariate analysis of OS 
and survival after relapse related to FLT3 ITD mutation status 
at diagnosis and relapse. FLT3 ITD mutation at relapse, irre-
spective of the initial mutation status, showed a statistically 
significant association with a poor prognosis on OS (HR, 
2.486; P=0.014) and survival after relapse (HR, 2.042; P= 
0.039). FLT3 ITD mutation at diagnosis did not show statisti-
cally significant prognostic impact on OS or survival after 
relapse.
DISCUSSION
In this study, the FLT3 ITD mutation was present in 20 
(29.0%) patients each at diagnosis and relapse, similar to 
the findings of a recent study [22]. Between diagnosis and 
relapse, the FLT3 ITD mutation status changed in 18 patients 
(26.1%). This figure is quite high relative to the recently 
reported value of 17.5%, and reflects the heterogeneity of 
FLT3 ITD mutation populations [24].
Patients with persistent FLT3 ITD mutation showed higher 
initial WBC counts than those with persistent wild-type Korean J Hematol 2011;46:88-95.
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status. Patients with loss of the FLT3 ITD mutation at relapse 
showed higher initial WBC count, blast percentage in PB 
and BM than those with persistent wild-type status, con-
sistent with the previous findings [11-16]. Patients who ac-
quired the FLT3 ITD mutation at relapse showed significantly 
shorter OS and survival after relapse than those with persis-
tent wild-type status, and similar differences were observed 
between patients who acquired the FLT3 ITD mutation at 
relapse and patients with persistent FLT3 ITD mutation. 
Additionally, patients with persistent FLT3 ITD mutation 
showed a significantly shorter duration of CR than those 
with persistent wild-type status. These findings were most 
pronounced in patients with FLT3 ITD mutation at relapse, 
compared to those with mutation-negative status at relapse, 
despite SCT being significantly more frequently performed 
after the first relapse in patients with FLT3 ITD mutation. 
Collectively, the results suggest that FLT3 ITD mutation 
at relapse is a poor prognostic indicator, and are consistent 
with recent data that reported a shorter time-to-relapse in 
patients with FLT3 ITD mutation at relapse compared to 
those without the mutation [24]. On the other hand, FLT3 
ITD mutation status at diagnosis influenced WBC count and 
blast percentage in PB and BM at diagnosis, but prognostic 
differences according to mutation status at diagnosis were 
not statistically significant. These differences between the 
prognostic potential of mutation status at diagnosis and re-
lapse may indicate that the prognostic impact of FLT3 ITD 
mutation status at relapse is more pronounced than the muta-
tion status at diagnosis in normal-karyotype AML patients 
with relapse. 
Multivariate analysis revealed the FLT3 ITD mutation at 
relapse to be an independent indicator of poor prognosis 
for both OS and survival after relapse. Otherwise, the pres-
ence of FLT3 ITD mutation at diagnosis did not show any 
prognostic effect. These results support our speculation that 
the impact of FLT3 I T D  m u t a t i o n  s t a t u s  a t  r e l a p s e  i s  o f  
greater prognostic value than the mutation status at diagnosis 
in normal-karyotype AML patients with relapse. Thus far, 
FLT3 ITD mutation status at diagnosis has been firmly estab-
lished as a prognostic indicator for normal-karyotype AML 
[25, 26]. Moreover, the ratio of mutant:wild-type cells has 
been suggested to be a possible prognostic indicator by a 
previous study, which showed significantly lower 5-year 
relapse-free survival rates (57% vs. 79%, P=0.048) in patients 
with a high mutant:wild-type ratio (≥0.66) than in those 
with a low ratio. However, in our study, not only did the 
FLT3 ITD mutation status at diagnosis not predict outcome 
but there was also no evidence of a prognostic impact of 
the relative amount of the mutant cells. One possible ex-
planation for the discordant results is the different nature 
of the patient group included in the analysis. Previous studies 
have focused on FLT3 ITD mutation status at initial diagnosis; 
therefore, all patients could be included into analysis regard-
less of their status at relapse. However, in our study, only 
patients who had undergone a relapse could be enrolled. 
Because the clinical outcome between relapsed and non- 
relapsed patients is quite different, this heterogeneity might 
influence the clinical outcome. 
Our study had some limitations. First, several molecular 
aberrations which have potential prognostic impacts in nor-
mal karyotype AML, such as CCAAT-enhancer binding pro-
tein-α ( CEBPA) and Wilm’s tumor 1 (WT1), were not 
analyzed. These factors may have influenced our results. 
Second, the number of patients was relatively small, which 
may lead to false positives or negatives and thus would have 
affected our conclusions. Third, although we found that a 
prognostic impact of NPM1 mutation was not evident at 
either diagnosis or relapse in patients in the absence of FLT3 
ITD mutation, this analysis suffered from low statistical pow-
er due to the limited number of patients. For this reason, 
we could not perform more categorized analysis based on 
the different mutation status combination of FLT3 ITD and 
NPM1, which has been widely used in recent studies. 
Therefore, further studies with larger patient populations 
will be required for more accurate analysis. 
In conclusion, patients with acquired or persistent FLT3 
ITD mutation at relapse showed significantly shorter OS 
and survival after relapse than those with persistent wild- 
type status. These statistical differences were most pro-
nounced in patients with FLT3 ITD mutation at relapse, 
when compared to those with mutation-negative status at 
this time point. However, the mutation status at diagnosis 
did not affect the outcome. Collectively, these results suggest 
that the impact of FLT3 ITD mutation status at relapse is 
expected to be of greater prognostic value than the mutation 
status at diagnosis in normal karyotype-AML patients with 
relapse.
REFERENCES
1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and 
leukemia. Blood 2002;100:1532-42.
2. Brasel K, Escobar S, Anderberg R, de Vries P, Gruss HJ, Lyman SD. 
Expression of the flt3 receptor and its ligand on hematopoietic 
cells. Leukemia 1995;9:1212-8.
3. Drexler HG. Expression of FLT3 receptor and response to FLT3 
ligand by leukemic cells. Leukemia 1996;10:588-99.
4. Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 
receptor expression on the surface of normal and malignant hu-
man hematopoietic cells. Blood 1996;88:3383-90.
5. Birg F, Courcoul M, Rosnet O, et al. Expression of the FMS/ 
KIT-like gene FLT3 in human acute leukemias of the myeloid and 
lymphoid lineages. Blood 1992;80:2584-93.
6. Carow CE, Levenstein M, Kaufmann SH, et al. Expression of the 
hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in hu-
man leukemias. Blood 1996;87:1089-96.
7. Stacchini A, Fubini L, Severino A, Sanavio F, Aglietta M, 
Piacibello W. Expression of type III receptor tyrosine kinases 
FLT3 and KIT and responses to their ligands by acute myeloid leu-
kemia blasts. Leukemia 1996;10:1584-91.
8. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia 
2003;17:1738-52.
9. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 Korean J Hematol 2011;46:88-95.
Prognosis of FLT3 ITD in relapsed AML 95
constitutively activates STAT5 and MAP kinase and introduces 
autonomous cell growth in IL-3-dependent cell lines. Oncogene 
2000;19:624-31.
10. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of 
D835 within the activation loop of FLT3 in human hematologic 
malignancies. Blood 2001;97:2434-9.
11. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal 
tandem duplication mutations in adult acute myeloid leukaemia 
define a high-risk group. Br J Haematol 2000;111:190-5.
12. Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance 
of activating FLT3 mutations in younger adults (16 to 60 years) 
with acute myeloid leukemia and normal cytogenetics: a study of 
the AML Study Group Ulm. Blood 2002;100:4372-80. 
13. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 
internal tandem duplication in patients with acute myeloid leuke-
mia (AML) adds important prognostic information to cytogenetic 
risk group and response to the first cycle of chemotherapy: analysis 
of 854 patients from the United Kingdom Medical Research 
Council AML 10 and 12 trials. Blood 2001;98:1752-9.
14. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 
and N-RAS gene mutations in acute myeloid leukemia. Blood 
1999;93:3074-80.
15. Kottaridis PD, Gale RE, Linch DC. Flt3 mutations and leukaemia. 
Br J Haematol 2003;122:523-38.
16. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating 
mutations in 979 patients with acute myelogenous leukemia: asso-
ciation with FAB subtypes and identification of subgroups with 
poor prognosis. Blood 2002;99:4326-35.
17. Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. 
FLT3 tyrosine kinase domain mutations are biologically distinct 
from and have a significantly more favorable prognosis than FLT3 
internal tandem duplications in patients with acute myeloid 
leukemia. Blood 2007;110:1262-70.
18. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 
mutations are associated with poor disease-free survival and a dis-
tinct gene-expression signature among younger adults with de no-
vo cytogenetically normal acute myeloid leukemia lacking FLT3 
internal tandem duplications. Blood 2008;111:1552-9. 
19. Mead AJ, Gale RE, Hills RK, et al. Conflicting data on the prog-
nostic significance of FLT3/TKD mutations in acute myeloid leu-
kemia might be related to the incidence of biallelic disease. Blood 
2008;112:444-5.
20. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and 
childhood acute myeloid leukaemia: towards definition of a new 
leukaemia entity. Hematol Oncol 2009;27:171-81.
21. Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors 
in acute myeloid leukemia. Crit Rev Oncol Hematol 2008;66: 
181-93. 
22. Huang Q, Chen W, Gaal KK, Slovak ML, Stein A, Weiss LM. A rap-
id, one step assay for simultaneous detection of FLT3/ITD and 
NPM1 mutations in AML with normal cytogenetics. Br J Haema-
tol 2008;142:489-92. 
23. Chillón MC, Santamaría C, García-Sanz R, et al. Long FLT3 in-
ternal tandem duplications and reduced PML-RARalpha ex-
pression at diagnosis characterize a high-risk subgroup of acute 
promyelocytic leukemia patients. Haematologica 2010;95:745- 
51. 
24. Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influ-
ence of FLT3 mutations in paired initial and relapsed AML 
samples. Leukemia 2006;20:1217-20. 
25. Kim YK, Kim HN, Lee SR, et al. Prognostic significance of nucleo-
phosmin mutations and FLT3 internal tandem duplication in 
adult patients with cytogenetically normal acute myeloid 
leukemia. Korean J Hematol 2010;45:36-45.
26. Chang SH, Lee NY, Kim DH, Sohn SK, Suh JS. FLT3 Gene 
Mutations as a Prognostic Factor for Acute Myeloid Leukemia. 
Korean J Lab Med 2006;26:233-40.